Therefore, we can speculate that targeting N-Cadherin could be a potential co-adjuvant therapy to be administered in combination with anti-tumoral drugs to prevent the engraftment and the dormancy of BrCa cells lodged in the endosteal niche. The gene discussed is CDH2; the disease is invasive breast carcinoma.